Zhiyi Biotech Reports Successful Phase I Results for SK10 in Chemotherapy-induced Diarrhea Treatment
Zhiyi Biotech, a pioneering clinical-stage biotech specializing in live biotherapeutic products (LBPs), has achieved significant milestones with its latest clinical trial results for SK10. The Phase I study, conducted in the United States, has demonstrated promising outcomes in the treatment of chemotherapy-induced diarrhea (CID) using SK10, an innovative heat-killed Bacteroides fragilis product. The randomized, double-blind,…
